Achieve Life Sciences, Inc.

ACHV

US0044685008

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 25/05/2024 am IST			5-day change	1st Jan Change
5.41 ^USD	0.00%		+6.92%	+31.31%

13/05	Oppenheimer Adjusts Achieve Life Sciences Price Target to $11 From $18, Maintains Outperform Rating	MT
09/05	Transcript : Achieve Life Sciences, Inc., Q1 2024 Earnings Call, May 09, 2024

Oncogenex Pharmaceuticals Inc. will Change its Name to Achieve Life Sciences, Inc

January 26, 2018 at 10:30 am IST

Effective January 26, 2018, Oncogenex Pharmaceuticals Inc. will change its name to Achieve Life Sciences, Inc.

Latest news about Achieve Life Sciences, Inc.

Oppenheimer Adjusts Achieve Life Sciences Price Target to $11 From $18, Maintains Outperform Rating	13/05	MT
Transcript : Achieve Life Sciences, Inc., Q1 2024 Earnings Call, May 09, 2024	10/05
Achieve Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine	06/05	CI
JonesTrading Starts Achieve Life Sciences With Buy Rating, $20 Price Target	17/04	MT
Transcript : Achieve Life Sciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024	29/03
Achieve Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Achieve Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/03	CI
Achieve Life Sciences, Inc. Announces Data from Cytisinicline ORCA Program to Be Presented at the 2024 Society for Research on Nicotine and Tobacco Annual Meeting	20/03	CI
Sector Update: Health Care Stocks Decline Late Afternoon	01/03	MT
Sector Update: Health Care	01/03	MT
Achieve Life Sciences Agrees on Safety Exposure Data for Smoking Cessation Medication as Part of NDA	01/03	MT
Top Midday Decliners	13/12	MT
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	12/12	MT
Oppenheimer Adjusts Achieve Life Sciences Price Target to $18 From $21, Maintains Outperform Rating	12/12	MT
Investors Await Inflation Data, Look to Last Fed Meeting of Year as US Futures Rise Slightly in Tuesday's Premarket	12/12	MT
Top Premarket Decliners	12/12	MT
Transcript : Achieve Life Sciences, Inc., Q3 2023 Earnings Call, Nov 09, 2023	10/11
Achieve Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Achieve Life Sciences, Inc.(NasdaqCM:ACHV) added to S&P Global BMI Index	18/23/18	CI
Achieve Life Sciences, Inc. Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting	11/23/11	CI
Transcript : Achieve Life Sciences, Inc., Q2 2023 Earnings Call, Aug 15, 2023	15/23/15
Achieve Life Sciences, Inc. Announces Positive Topline Results from A Second Phase 3 ORCA-3 Trial	15/23/15	CI
Achieve Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association	11/23/11	CI

Chart Achieve Life Sciences, Inc.

Duration

Period

More charts

Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Companyâs product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over the counter (OTC) products.

Sector

Biotechnology & Medical Research

Calendar

05/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.41 USD

Average target price

19 USD

Spread / Average Target

+251.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ACHIEVE LIFE SCIENCES, INC.	+31.31%	186M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+44.98%	40.65B
CELLTRION, INC.	-10.87%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research

Achieve Life Sciences, Inc.

Equities

ACHV

US0044685008

Biotechnology & Medical Research

Oncogenex Pharmaceuticals Inc. will Change its Name to Achieve Life Sciences, Inc

Latest news about Achieve Life Sciences, Inc.

Chart Achieve Life Sciences, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research